Walvax Biotechnology Co., Ltd. is a leading biopharmaceutical company based in China, focusing on the research, development, and commercialization of vaccines and biopharmaceutical products. Established in 2001, the company aims to contribute to global public health by providing advanced preventive healthcare solutions. Walvax's portfolio includes a range of vaccines targeting infectious diseases such as hepatitis, Haemophilus influenza type b (Hib), and pneumococcal infections, addressing critical areas in preventive medicine.

The company plays a significant role in the healthcare and biotechnology sectors, impacting public health initiatives and contributing to the prevention of epidemic outbreaks. With a commitment to innovation, Walvax invests heavily in research and development, forming collaborative partnerships with global healthcare organizations to advance vaccine technology. Its operations are crucial in supporting vaccination programs and enhancing accessibility to essential vaccines. As a publicly traded entity, Walvax Biotechnology Co., Ltd. is pivotal not only in its domestic market but also increasingly influential in international markets, reflecting its growing importance in global health security.